SCHEMBL14744869

SCHEMBL14744869

CCc1c(O)c(C(=O)OC)c(=O)n(Cc2ccc(OC)cc2OC)c1-c1ccc2c(c1)cc1n2CCN(C(=O)O)C1C(C)(C)C

nearest known ligand 0.35

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
AADAT Q8N5Z0 2/20 0.35
EDNRB P24530 5/20 0.34
ALDH1A1 P00352 5/20 0.34
TSHR P16473 1/20 0.34
MEN1 O00255 4/20 0.33
KMT2A Q03164 4/20 0.33
MAPT P10636 2/20 0.32
TP53 P04637 1/20 0.32
KDM4E B2RXH2 2/20 0.32
PLA2G2A P14555 1/20 0.32
POLB P06746 2/20 0.32
TDP1 Q9NUW8 1/20 0.32
NR3C2 P08235 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
RECQL P46063 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14744868 0.80 NR1H2 (0.37) AADATEDNRBALDH1A1MEN1KMT2A
SCHEMBL14745171 0.79 MAPT (0.37) AADATALDH1A1TSHRMEN1KMT2A
SCHEMBL14744693 0.77 L3MBTL1 (0.38) EDNRBALDH1A1TSHRMAPTTP53
SCHEMBL16568122 0.77 MEN1 (0.41) EDNRBALDH1A1MEN1KMT2AMAPT
SCHEMBL14744705 0.75 EDNRB (0.34) EDNRBALDH1A1MAPTTP53PLA2G2A
SCHEMBL14744918 0.74 AADAT (0.38) AADATEDNRBALDH1A1TSHRMEN1
SCHEMBL16568228 0.73 HTT (0.43) AADATALDH1A1MEN1KMT2AMAPT
SCHEMBL14744953 0.73 LMNA (0.39) AADATEDNRBALDH1A1TSHRMEN1
SCHEMBL14744669 0.72 EDNRB (0.43) EDNRBALDH1A1TSHRKDM4EPLA2G2A
SCHEMBL14744608 0.72 EDNRB (0.42) EDNRBALDH1A1TSHRMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9409905-B2 Antibacterial compounds and methods for use PTC THERAPEUTICS, INC. (US) 2016-08-09 US disclosed
US-20150038437-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS, INC. (US) 2015-02-05 US disclosed
EP-2750504-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC Therapeutics, Inc. (US) 2014-07-09 EP disclosed
WO-2013033258-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS, INC. (US) 2013-03-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150038437-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE MRPL21, SLC11A2, CLPP AADAT 1779/4885EDNRB 3885/4885ALDH1A1 3792/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.